Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
      QxMD      Google Scholar   
Citation:
JAMA vol 317 (1) 48-58
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
2281  
Children:
None
Program:
CCP
Primary Committee:
Symptom Inter
Sec. Committees:
Health Outcomes    
Pharmas:
 
Grants:
UL1 TR001070, U10 CA047577, U10 CA052784, U10 CA077658, UG1 CA189870, UG1 CA189825, UL1 TR001863, U10 CA035279, U10 CA037404, UG1 CA189805, U10 CA059518, UG1 CA189861, U10 CA045418, U10 CA180836, U10 CA077440, U10 CA180857, U10 CA037447, U10 CA180850, UG1 CA189817, U10 CA035272, UG1 CA189850, UG1 CA189830, U10 CA041287, UG1 CA189823, U10 CA047559, U10 CA180790, UG1 CA189853, UG1 CA189819, U10 CA074811, U10 CA180833, P30 CA016359, U10 CA180867, U10 CA180866  
Corr. Author:
 
Authors:
                               
Networks:
CHRISTIANA, HEARTLAND, LAPS-MN026, LAPS-NY158, NH038, NY021, VCU   
Study
CALGB-79804
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-70604, CALGB-150804
Phases:
N/A, 3, N/A
Keywords:
Article